153 related articles for article (PubMed ID: 37715448)
1. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
Ishibashi R; Hirayama K; Watanabe S; Okano K; Kuroda Y; Baba Y; Kanayama T; Ito C; Kasahara K; Aiba S; Iga R; Ohtani R; Inaba Y; Koshizaka M; Maezawa Y; Yokote K
J Diabetes Investig; 2023 Dec; 14(12):1419-1422. PubMed ID: 37715448
[TBL] [Abstract][Full Text] [Related]
2. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
3. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
Huang CH; Huang YY; Hsu BR
Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
[TBL] [Abstract][Full Text] [Related]
4. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation.
Suzuki S; Hinokio Y; Ohtomo M; Hirai M; Hirai A; Chiba M; Kasuga S; Satoh Y; Akai H; Toyota T
Diabetologia; 1998 May; 41(5):584-8. PubMed ID: 9628277
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
6. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
7. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Johansson KS; Brønden A; Knop FK; Christensen MB
Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.
Huang W; Whitelaw J; Kishore K; Neto AS; Holmes NE; Marhoon N; Bellomo R; Ekinci EI
J Diabetes Complications; 2023 Aug; 37(8):108522. PubMed ID: 37311358
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
14. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis.
Oh S; Purja S; Shin H; Kim M; Kim E
Diab Vasc Dis Res; 2022; 19(3):14791641221106866. PubMed ID: 35686694
[TBL] [Abstract][Full Text] [Related]
16. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.
Du Y; Bai L; Fan B; Ding H; Ding H; Hou L; Ma H; Xing N; Wang F
Prim Care Diabetes; 2022 Feb; 16(1):156-161. PubMed ID: 34930687
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study.
Oda T; Satoh M; Nagasawa K; Sasaki A; Hasegawa Y; Takebe N; Ishigaki Y
Diabetes Ther; 2022 Sep; 13(9):1635-1643. PubMed ID: 35895275
[TBL] [Abstract][Full Text] [Related]
19. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
20. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs.
Alkabbani W; Gamble JM; Eurich DT; Minhas-Sandhu JK; Shah BR; Alsabbagh MW; Zongo A
Diabetes Metab; 2022 Mar; 48(2):101305. PubMed ID: 34808344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
